-
Jun 24, 2024 | 
onclive.com | Arndt Vogel
Camrelizumab Plus Rivoceranib vs Sorafenib as First-Line Therapy for Unresectable Hepatocellular Carcinoma (uHCC): Final Overall Survival Analysis of the Phase 3 CARES-310 StudyThis is a final overall survival analysis on the phase 3 CARES-310 study (NCT03764293), a randomized, open-label, international phase 3 trial comparing camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC).
-
Jun 2, 2024 | 
onclive.com | Arndt Vogel
Author(s):Arndt Vogel, MD, on the final overall survival data for camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma.
-
Nov 23, 2023 | 
nature.com | Arndt Vogel
AbstractFOLFOXIRI plus bevacizumab has demonstrated benefits for metastatic colorectal cancer (mCRC) patients. However, challenges arise in its clinical implementation due to expected side effects and a lack of stratification criteria. The AIO “CHARTA” trial randomised mCRC patients into clinical Group 1 (potentially resectable), 2 (unresectable/risk of rapid progression), or 3 (asymptomatic). They received FOLFOX/bevacizumab +/− irinotecan.
-
Oct 24, 2023 | 
onclive.com | Rachna T Shroff |Arndt Vogel |Amit Singal
Rivoceranib plus Camrelizumab for First-Line Treatment of HCC: Data from CARES-310Rachna Shroff, MD, MS, FASCO, shares data from the CARES-310 study showing improved progression-free and overall survival in patients with hepatocellular carcinoma treated with camrelizumab and rivoceranib compared to sorafenib, regardless of liver function.
-
Oct 24, 2023 | 
onclive.com | Rachna T Shroff |Arndt Vogel |Amit Singal
Key Outcomes Data in Patients With HCC Based on Liver FunctionAmit Singal, MD, reviews analyses of the HIMALAYA and KEYNOTE-240 trials, focusing on the impact of liver function via ALBI grades on treatment outcomes and safety in patients with hepatocellular carcinoma.
-
Oct 17, 2023 | 
onclive.com | Rachna T Shroff |Arndt Vogel |Amit Singal
Assessing Liver Function in Patients With HCC: The MELD ScoreRachna Shroff, MD, MS, FASCO, and Amit Singal, MD, discuss the use of various liver function assessment scores—Child-Pugh, ALBI, and MELD—in the care of patients with hepatocellular carcinoma, emphasizing their pros, cons, and roles in treatment decision-making.
-
Oct 10, 2023 | 
onclive.com | Rachna T Shroff |Arndt Vogel |Amit Singal
Assessing Liver Function in Patients With HCC: The Child-Pugh ScoreArndt Vogel, MD, explains that the Child-Pugh score, although simpler to calculate than the ALBI score, sometimes lacks granularity in assessing liver function in hepatocellular carcinoma patients; however, both scoring systems are considered valuable tools in clinical settings and trials for evaluating liver function's prognostic impact on treatment outcomes.
-
Oct 10, 2023 | 
onclive.com | Rachna T Shroff |Arndt Vogel |Amit Singal
Assessing Liver Function in Patients With HCC: The ALBI ScoreThe ALBI score, originally developed to stratify cirrhotic patients undergoing resection, has evolved into a vital tool for assessing prognosis and treatment efficacy in various stages of hepatocellular carcinoma and is now being explored for its utility in other liver-related diseases.
-
Oct 2, 2023 | 
onclive.com | Rachna T Shroff |Arndt Vogel |Amit Singal
Rachna Shroff, MD, MS, FASCO, discusses hepatocellular carcinoma, noting its rising global incidence and identifying underlying liver cirrhosis as a key risk factor influenced by conditions like viral hepatitis and fatty liver disease; diagnosis often involves radiographic imaging and triple-phase CT and MRI scans, while treatment necessitates a multidisciplinary approach involving hepatologists, surgeons, and other specialists.
-
Oct 2, 2023 | 
onclive.com | Rachna T Shroff |Arndt Vogel |Amit Singal
Drs Vogel and Singal discuss the critical importance of assessing liver function in hepatocellular carcinoma patients, as it impacts prognosis and treatment strategies; they mention the evolution from Child-Pugh scoring to the ALBI score, which uses albumin and bilirubin levels, for a more objective evaluation of liver health.
